TriAgenics, a pioneer in fully guided tooth bud ablation, announced the granting of four European patents, further strengthening the company’s global intellectual property position for a new technology to prevent third molar formation. Germany, France, Italy and the United Kingdom are the latest European countries to be granted patents for TriAgenics’ ablation probe system.
TriAgenics’ patented microablation technology is the cornerstone of Zero3 TBA, a preventative care treatment for children aged 6-12 years. The treatment prevents third molar formation by applying low-intensity CT-guided microwave energy.
This new dental treatment is based on microwave ablation technology commonly used in medicine. TriAgenics plans to introduce Zero3 TBA to the U.S. dental market in 2025, subject to approval by the U.S. Food and Drug Administration (FDA).
Once FDA approval is obtained, dentists will send their patients’ CBCT and intraoral scans to TriAgenics, which will create a customized Zero3 kit and send it to the dentist for a one-minute treatment utilizing TriAgenics’ proprietary ablation technology.
TriAgenics believes that Zero3 TBA treatment will have significant economic benefits. In the United States alone, the total expenditure on third molar extraction and related correction is estimated to be close to $5 billion.
TriAgenics estimates that once Zero3 TBA treatment becomes the new standard of care in the United States, its potential market size will exceed $2.5 billion per year.
Related topics:
